The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration, a leading cause of blindness in adults over 55. Developed by LumiThera Inc., the device showed ...

These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

Age-related macular degeneration ... drops to mice with induced dry AMD. The treated group exhibited retinal cell protection and significantly reduced retinal degeneration, comparable to normal ...

Opticians, now more often called optometrists, will be able to use the software subsequently developed as a predictive or ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

PST-611-CT1 is a first-in-human single ascending dose trial aiming to confirm the favorable safety profile of the drug and validate the maximal dose for the Phase II proof-of-concept study, in six to ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Izervay (avacincaptad pegol) is a prescription injection used to treat severe age-related macular degeneration ... severe vision loss than dry AMD. During Izervay treatment, your doctor will ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.

Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...